NDC 0053-7212 - Zemaira
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0053-7212
- Package NDCs from labels
- 0053-7212-01
- Manufacturer
- CSL Behring LLC
- Effective date
- 2024-09-23
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Zemaira - CSL Behring LLC | CSL Behring LLC | 2024-09-23 | PLASMA DERIVATIVE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0053-7212-01 | ZEMAIRA | 76 mL in 1 VIAL, SINGLE-USE | INJECTION, POWDER, LYOPHILIZED, | 76 mL | 4000 mg in 76mL | 27 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| alpha-1-proteinase inhibitor human | ACTIVE INGREDIENT | F43I396OIS | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| alpha-1-proteinase inhibitor human | ACTIVE MOIETY | F43I396OIS | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| hydrochloric acid | INACTIVE INGREDIENT | QTT17582CB | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| Mannitol | INACTIVE INGREDIENT | 3OWL53L36A | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| Sodium Chloride | INACTIVE INGREDIENT | 451W47IQ8X | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 | |
| Sodium Phosphate | INACTIVE INGREDIENT | SE337SVY37 | ZEMAIRA (ALPHA-1-PROTEINASE INHIBITOR HUMAN) KIT [CSL BEHRING LLC] | 16 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lactated Ringers | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE | Baxter Healthcare Corporation | f09f80bf-2f8b-4420-865d-aec2d5e5cd4d | 2012-06-12 | 451W47IQ8X | |
| bcda2379-fca3-4e76-b8de-0d5476f92995 | 0c3354b5-a1d8-4f98-ad55-2eafe4265c4e | 2010-09-29 | Warnings, Adverse reactions | 0c3354b5-a1d8-4f98-ad55-2eafe4265c4e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.